Published 6 issues per year
ISSN Print: 1040-8401
ISSN Online: 2162-6472
Indexed in
p53-Based Immunotherapy of Cancer
ABSTRACT
Immunotherapy targeting p53 missense mutations, which occur in nearly half of all human tumors, is limited by several factors, including the constraints of antigen processing and presentation. Due to the accumulation of mutated p53 molecules in tumors expressing p53 mutations, an alternative approach would be to target wild-type sequence, CTL-defined p53 epitopes. Obviously, the possibility of an autoimmune response is a major potential drawback to this therapy. Immunization of BALB/c mice with bone marrow-derived dendritic cells (DC) generated in the presence of GM-CSF/IL-4 and prepulsed with the H-2Kd-binding wild-type p53232-240 peptide has been shown to induce anti-peptide CTL. These effectors were cross-reactive against sarcomas expressing p53 missense mutations outside of the p53232-240 epitope, but not within it. Mitogen-activated splenocytes, which express elevated levels of p53, were not sensitive to these CTL. The p53 peptide-pulsed DC-based vaccine was shown to be effective in inducing tumor rejection in immunization and therapy models in the absence of any observable deleterious effect on naive mice. The murine model has now been extended to include the use of genetically modified DC-based vaccines as well.
-
Barrett John, Childs Richard, The Benefits of an Alloresponse: Graft-Versus-Tumor, Journal of Hematotherapy & Stem Cell Research, 9, 3, 2000. Crossref
-
Hoffmann Thomas K., Bier Henning, Whiteside Theresa L., Targeting the immune system: novel therapeutic approaches in squamous cell carcinoma of the head and neck, Cancer Immunology, Immunotherapy, 53, 12, 2004. Crossref
-
Tewari Mallika, Sahai Shipra, Mishra Raghvendra R., Shukla Sunit K., Shukla Hari S., Dendritic cell therapy in advanced gastric cancer: A promising new hope?, Surgical Oncology, 21, 3, 2012. Crossref
-
Shibuya Terry Y., Lum Lawrence G., Pawlowski Tomasz, Whiteside Theresa L., Immunology and Immunotherapy of Head and Neck Cancer, in Head and Neck Cancer, 2003. Crossref
-
Troudi W., Sadkaoui S., Yacoubi Loueslati B., Ben Abdallah M., Ben Ayoub W., Mrad K., Ben Ayed F., Ben Romdhane K., Benammar El Gaaied A., Analyse de la rupture de tolérance vis-à-vis de la p53 dans le cancer du sein en Tunisie, Immuno-analyse & Biologie Spécialisée, 21, 1, 2006. Crossref
-
Tong Charles C. L., Kao Johnny, Sikora Andrew G., Recognizing and reversing the immunosuppressive tumor microenvironment of head and neck cancer, Immunologic Research, 54, 1-3, 2012. Crossref
-
Menendez Daniel, Shatz Maria, Resnick Michael A., Interactions between the tumor suppressor p53 and immune responses, Current Opinion in Oncology, 25, 1, 2013. Crossref
-
Melief Cornelis J.M., Toes RenéE.M., Medema Jan Paul, Van Der Burg Sjoerd H., Ossendorp Ferry, Offringa Rienk, Strategies for immunotherapy of cancer, in Advances in Immunology Volume 75, 75, 2000. Crossref
-
Cicinnati Vito R., Dworacki Grzegorz, Albers Andreas, Beckebaum Susanne, Tüting Thomas, Kaczmarek Elzbieta, DeLeo Albert B., Impact of p53-based immunization on primary chemically-induced tumors, International Journal of Cancer, 113, 6, 2005. Crossref
-
Hoffmann T. K., Whiteside T. L., Bier H., Plattenepithelkarzinome des Kopf-Hals-Bereichs, HNO, 53, 3, 2005. Crossref
-
Schuler P.J., Hoffmann T.K., Gauler T.C., Bergmann C., Brandau S., Lang S., Immuntherapie von Kopf-Hals-Karzinomen, HNO, 61, 7, 2013. Crossref
-
Hoffmann Thomas K., Schuler Patrick J., Antigen-specific immunotherapy in head and neck cancer, Advances in Cellular and Molecular Otolaryngology, 1, 1, 2013. Crossref
-
Cicinnati Vito R., Zhang Xia, Yu Zhengya, Ferencik Stanislav, Schmitz Klaus J., Dworacki Grzegorz, Kaczmarek Elzbieta, Oldhafer Karl, Frilling Andrea, Baba Hideo A., Schmid Kurt W., Grosse-Wilde Hans, Broelsch Christoph E., DeLeo Albert B., Gerken Guido, Beckebaum Susanne, Increased frequencies of CD8+ T lymphocytes recognizing wild-type p53-derived epitopes in peripheral blood correlate with presence of epitope loss tumor variants in patients with hepatocellular carcinoma, International Journal of Cancer, 119, 12, 2006. Crossref
-
Suzuki Kazufumi, Matsubara Hisahiro, Recent Advances in p53 Research and Cancer Treatment, Journal of Biomedicine and Biotechnology, 2011, 2011. Crossref
-
Chène Patrick, p53 as a drug target in cancer therapy, Expert Opinion on Therapeutic Patents, 11, 6, 2001. Crossref
-
Stegh Alexander H, Targeting the p53 signaling pathway in cancer therapy – the promises, challenges and perils, Expert Opinion on Therapeutic Targets, 16, 1, 2012. Crossref
-
Ferriès Estelle, Connan Francine, Pagès Franck, Gaston Jésintha, Hagnéré Anne-Marie, Vieillefond Annick, Thiounn Nicolas, Guillet Jean-Gérard, Choppin Jeannine, Identification of p53 peptides recognized by CD8+ T lymphocytes from patients with bladder cancer, Human Immunology, 62, 8, 2001. Crossref
-
Björck Pia, Lie Wen-Rong, Woulfe Susan L., Klein Barbara K., Olson Walter, Storkus Walter J., Progenipoietin-generated dendritic cells exhibit anti-tumor efficacy in a therapeutic murine tumor model, International Journal of Cancer, 100, 5, 2002. Crossref
-
Würtzen Peter A., Claesson Mogens H., A HLA-A2 restricted human CTL line recognizes a novel tumor cell expressed p53 epitope, International Journal of Cancer, 99, 4, 2002. Crossref
-
Radhakrishnan Vivek, S. Swanson Mark, K. Sinha Uttam, Monoclonal Antibodies as Treatment Modalities in Head and Neck Cancers, AIMS Medical Science, 2, 4, 2015. Crossref
-
Weinberg Robert A, How TP53 (almost) became an oncogene, Journal of Molecular Cell Biology, 11, 7, 2019. Crossref
-
Hoffmann Thomas K., Nakano Koji, Elder Elaine M., Dworacki Grzegorz, Finkelstein Sydney D., Appella Ettore, Whiteside Theresa L., DeLeo Albert B., Generation of T Cells Specific for the Wild-Type Sequence p53264–272 Peptide in Cancer Patients: Implications for Immunoselection of Epitope Loss Variants, The Journal of Immunology, 165, 10, 2000. Crossref
-
Fedoseyeva Eugenia V., Boisgérault Florence, Anosova Natalie G., Wollish Wendy S., Arlotta Paola, Jensen Peter E., Ono Santa J., Benichou Gilles, CD4+T Cell Responses to Self- and Mutated p53 Determinants During Tumorigenesis in Mice, The Journal of Immunology, 164, 11, 2000. Crossref
-
Hoffmann Thomas K., Loftus Douglas J., Nakano Koji, Maeurer Markus J., Chikamatsu Kazuaki, Appella Ettore, Whiteside Theresa L., DeLeo Albert B., The Ability of Variant Peptides to Reverse the Nonresponsiveness of T Lymphocytes to the Wild-Type Sequence p53264–272 Epitope, The Journal of Immunology, 168, 3, 2002. Crossref
-
Venuti Aldo, Progress and challenges in the vaccine-based treatment of head and neck cancers, Journal of Experimental & Clinical Cancer Research, 28, 1, 2009. Crossref
-
Ho Jenny J.L., Kim Young S., Biliopancreatic malignancy: Future prospects for progress, Annals of Oncology, 10, 1999. Crossref
-
Agupitan Arjelle Decasa, Neeson Paul, Williams Scott, Howitt Jason, Haupt Sue, Haupt Ygal, P53: A Guardian of Immunity Becomes Its Saboteur through Mutation, International Journal of Molecular Sciences, 21, 10, 2020. Crossref
-
Liu Yun-Cai, Ubiquitin Ligases and the Immune Response, Annual Review of Immunology, 22, 1, 2004. Crossref
-
Baar Joseph, Clinical Applications of Dendritic Cell Cancer Vaccines, The Oncologist, 4, 2, 1999. Crossref
-
Zöchbauer-Müller Sabine, Gazdar Adi F., Minna John D., Molecular Pathogenesis of Lung Cancer, Annual Review of Physiology, 64, 1, 2002. Crossref
-
Murakami Takayoshi, Tokunaga Naoyuki, Waku Toshihiko, Gomi Shinya, Kagawa Shunsuke, Tanaka Noriaki, Fujiwara Toshiyoshi, Antitumor Effect of Intratumoral Administration of Bone Marrow-Derived Dendritic Cells Transduced with Wild-Type p53 Gene, Clinical Cancer Research, 10, 11, 2004. Crossref
-
Cheok Chit Fang, Verma Chandra S., Baselga José, Lane David P., Translating p53 into the clinic, Nature Reviews Clinical Oncology, 8, 1, 2011. Crossref
-
Leibowitz Michael S., Nayak Jayakar V., Ferris Robert L., Head and neck cancer immunotherapy: Clinical evaluation, Current Oncology Reports, 10, 2, 2008. Crossref